Peptide biotech intelligence

The AI Intelligence Platform for Peptide Biotechnology.

Track peptide companies, clinical trials, FDA events, and biotechnology research from one platform.

Start Your 30-Day Free Trial Explore companies →⚡ Compare LLY vs NVO

Companies tracked

Peptides profiled

Trials indexed

Catalysts scheduled

Last updated:Jul 15, 2026Source:ClinicalTrials.gov, FDA.gov, SEC EDGARVerified:Manually reviewed by PeptidePlanet research teamData provider:PeptidePlanet Research

Trending companies

Public biotechs developing peptide therapeutics

All companies →

TickerCompanyFocusPipelineTrials

NVONovo NordiskGLP-1 analogs, amylin, and combination peptides83 LLYEli LillyIncretin therapies (GLP-1 / GIP / glucagon triagonists)63 ZEALZealand PharmaPeptide therapeutics (amylin, glucagon, GLP-2)51 AMGNAmgenBispecific peptide antibody conjugates31 VKTXViking TherapeuticsDual GLP-1/GIP receptor agonists31 GPCRStructure TherapeuticsOral small-molecule GLP-1 (peptide-adjacent)20

Upcoming events

FDA catalysts and clinical readouts

Full calendar →

Data unavailable

No upcoming catalysts on file.

Trial history

Recently completed peptide clinical trials

All trials →

Phase 3NCT04255433

SURMOUNT — tirzepatide in obesity

Eli Lilly · Obesity · n = 2,539

Phase 3NCT04184622

SURPASS — tirzepatide in T2D

Eli Lilly · Type 2 Diabetes · n = 1,879

Phase 3NCT03693430

STEP — semaglutide in obesity

Novo Nordisk · Obesity · n = 1,961

Phase 3NCT03574597

SUSTAIN — semaglutide long-term outcomes

Novo Nordisk · Type 2 Diabetes · n = 1,200

Pipeline activity

Investigational peptides in active development

Full pipeline →

GIP / GLP-1 / glucagon triple agonist

Phase 3

Retatrutide

Eli Lilly · Obesity, Type 2 Diabetes

GLP-1 / glucagon dual agonist

Phase 3

Survodutide

Zealand Pharma · Obesity, MASH

Long-acting amylin analog

Phase 3

Cagrilintide

Novo Nordisk · Obesity

GIPR antagonist / GLP-1 agonist peptide-antibody

Phase 2

MariTide

Amgen · Obesity

Dual GLP-1 / GIP agonist

Phase 2

VK2735

Viking Therapeutics · Obesity

Oral small-molecule GLP-1

Phase 2

GSBR-1290

Structure Therapeutics · Obesity, Type 2 Diabetes

Latest research

Peer-reviewed peptide research

Data unavailable

A verified research feed is not yet connected.

We only display research pulled from cited primary sources. This feed launches once our editorial pipeline is verified end-to-end.

AI Research Assistant

Ask questions. Get cited answers.

The assistant only answers using verified sources in our database. Every response includes citations. It refuses medical, dosing, purchasing, and personalized investment questions.

Try the assistant See plans

$ ask

Which companies have Phase 3 GLP-1 / GIP / glucagon triagonists in obesity?

→ answer

Eli Lilly is advancing retatrutide (LY3437943), a triagonist targeting GIP, GLP-1, and glucagon receptors, in Phase 3 for obesity and type 2 diabetes.^[1]

[1] clinicaltrials.gov · NCT05929066 · TRIUMPH program